Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
PRIMARY OBJECTIVES:
I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard.
II. Assess the impact of 18F-TFB PET/CT on clinical management.
OUTLINE:
Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has biopsy-proven papillary or follicular thyroid cancer
Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan
Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan
Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent)
Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min)
Age 18 or older
Ability to understand a written informed consent document, and the willingness to sign it
Subject is not pregnant
You may not be if
Contrast-enhanced CT within 4 last weeks
Amiodarone within last 4 months
Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks
Unable to lie flat, still or tolerate a PET scan
Applied betadine, iodoform, or quick tanning products to skin within last two weeks
If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25